These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 17922031)

  • 1. The RhoGEF domain of p210 Bcr-Abl activates RhoA and is required for transformation.
    Sahay S; Pannucci NL; Mahon GM; Rodriguez PL; Megjugorac NJ; Kostenko EV; Ozer HL; Whitehead IP
    Oncogene; 2008 Mar; 27(14):2064-71. PubMed ID: 17922031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p38 MAPK-mediated activation of NF-kappaB by the RhoGEF domain of Bcr.
    Korus M; Mahon GM; Cheng L; Whitehead IP
    Oncogene; 2002 Jul; 21(30):4601-12. PubMed ID: 12096337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contributions of the RhoGEF activity of p210 BCR/ABL to disease progression.
    Tala I; Chen R; Hu T; Fitzpatrick ER; Williams DA; Whitehead IP
    Leukemia; 2013 Apr; 27(5):1080-9. PubMed ID: 23207522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Examination of clinically-derived p210 BCR/ABL1 RhoGEF mutations in a murine bone marrow transplantation model of CML.
    Ciccarelli BT; Hu T; Wang Q; Kim JJ; Whitehead IP
    Leuk Res; 2020 Oct; 97():106440. PubMed ID: 32892149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p210(Bcr-Abl) desensitizes Cdc42 GTPase signaling for SDF-1alpha-directed migration in chronic myeloid leukemia cells.
    Chang YC; Tien SC; Tien HF; Zhang H; Bokoch GM; Chang ZF
    Oncogene; 2009 Nov; 28(46):4105-15. PubMed ID: 19718053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The coiled-coil domain and Tyr177 of bcr are required to induce a murine chronic myelogenous leukemia-like disease by bcr/abl.
    He Y; Wertheim JA; Xu L; Miller JP; Karnell FG; Choi JK; Ren R; Pear WS
    Blood; 2002 Apr; 99(8):2957-68. PubMed ID: 11929787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of p21 RAS in p210 bcr-abl transformation of murine myeloid cells.
    Mandanas RA; Leibowitz DS; Gharehbaghi K; Tauchi T; Burgess GS; Miyazawa K; Jayaram HN; Boswell HS
    Blood; 1993 Sep; 82(6):1838-47. PubMed ID: 7691239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protein tyrosine phosphatase 1B antagonizes signalling by oncoprotein tyrosine kinase p210 bcr-abl in vivo.
    LaMontagne KR; Flint AJ; Franza BR; Pandergast AM; Tonks NK
    Mol Cell Biol; 1998 May; 18(5):2965-75. PubMed ID: 9566916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SH1 domain autophosphorylation of P210 BCR/ABL is required for transformation but not growth factor independence.
    Pendergast AM; Gishizky ML; Havlik MH; Witte ON
    Mol Cell Biol; 1993 Mar; 13(3):1728-36. PubMed ID: 8441409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The SH2 domain of P210BCR/ABL is not required for the transformation of hematopoietic factor-dependent cells.
    Ilaria RL; Van Etten RA
    Blood; 1995 Nov; 86(10):3897-904. PubMed ID: 7579359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The src homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase.
    Roumiantsev S; de Aos IE; Varticovski L; Ilaria RL; Van Etten RA
    Blood; 2001 Jan; 97(1):4-13. PubMed ID: 11133737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Invadopodia and rolling-type motility are specific features of highly invasive p190(bcr-abl) leukemic cells.
    Daubon T; Rochelle T; Bourmeyster N; Génot E
    Eur J Cell Biol; 2012; 91(11-12):978-87. PubMed ID: 22717125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of the c-jun gene in p210 BCR-ABL transformed cells corresponds with activity of JNK, the c-jun N-terminal kinase.
    Burgess GS; Williamson EA; Cripe LD; Litz-Jackson S; Bhatt JA; Stanley K; Stewart MJ; Kraft AS; Nakshatri H; Boswell HS
    Blood; 1998 Oct; 92(7):2450-60. PubMed ID: 9746785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Dbl homology domain of BCR is not a simple spacer in P210BCR-ABL of the Philadelphia chromosome.
    Kin Y; Li G; Shibuya M; Maru Y
    J Biol Chem; 2001 Oct; 276(42):39462-8. PubMed ID: 11502748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity.
    Li S; Ilaria RL; Million RP; Daley GQ; Van Etten RA
    J Exp Med; 1999 May; 189(9):1399-412. PubMed ID: 10224280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ubiquitin-mediated interaction of p210 BCR/ABL with β-catenin supports disease progression in a murine model for chronic myelogenous leukemia.
    Chen R; Hu T; Mahon GM; Tala I; Pannucci NL; Ozer HL; Whitehead IP
    Blood; 2013 Sep; 122(12):2114-24. PubMed ID: 23950177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential interaction and activation of Rho family GTPases by p210bcr-abl and p190bcr-abl.
    Harnois T; Constantin B; Rioux A; Grenioux E; Kitzis A; Bourmeyster N
    Oncogene; 2003 Sep; 22(41):6445-54. PubMed ID: 14508524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TAT-CC fusion protein depresses the oncogenicity of BCR-ABL in vitro and in vivo through interrupting its oligomerization.
    Huang ZL; Gao M; Ji MS; Tao K; Xiao Q; Zhong L; Zeng JM; Feng WL
    Amino Acids; 2013 Feb; 44(2):461-72. PubMed ID: 22782217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The CRISPR/Cas9 system efficiently reverts the tumorigenic ability of BCR/ABL in vitro and in a xenograft model of chronic myeloid leukemia.
    García-Tuñón I; Hernández-Sánchez M; Ordoñez JL; Alonso-Pérez V; Álamo-Quijada M; Benito R; Guerrero C; Hernández-Rivas JM; Sánchez-Martín M
    Oncotarget; 2017 Apr; 8(16):26027-26040. PubMed ID: 28212528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protein tyrosine phosphatase PTP1B suppresses p210 bcr-abl-induced transformation of rat-1 fibroblasts and promotes differentiation of K562 cells.
    LaMontagne KR; Hannon G; Tonks NK
    Proc Natl Acad Sci U S A; 1998 Nov; 95(24):14094-9. PubMed ID: 9826659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.